文献速递心脑血管急症儿科与产科急症重症综合管理与镇静镇痛

美国儿童流感相关急性坏死性脑病

Influenza-Associated Acute Necrotizing Encephalopathy in US Children.
PubMed 文献 · JAMA · 2025-01-01
一句话结论美国多中心病例系列显示,流感相关急性坏死性脑病患儿病死率27%,存活者63%至少中度残疾,多数病前健康且未接种流感疫苗。

该研究为多中心病例系列,纳入2023年10月1日至2025年5月30日美国23家医院报告的41例21岁及以下流感相关急性坏死性脑病患儿。临床表现以发热(93%)、脑病(100%)和癫痫发作(68%)为主,95%为甲型流感。78%接受基因检测的患儿中47%携带可能与急性坏死性脑病风险相关的遗传风险等位基因,包括34%的RANBP2变异。多数患儿接受多种免疫调节治疗,包括甲泼尼龙(95%)、静脉注射免疫球蛋白(66%)和托珠单抗(51%)。11例(27%)死亡,中位死亡时间为症状出现后3天;27例存活者中63%在90天随访时改良Rankin量表评分≥3。

要点

  • 41例患儿中11例(27%)死亡,中位死亡时间为症状出现后3天(IQR 2-4),主要死因为脑疝(91%)。
  • 27例存活者中63%在90天随访时改良Rankin量表评分≥3,即至少中度残疾。
  • 38例有疫苗接种史的患儿中仅6例(16%)接种了适龄季节性流感疫苗。
  • 32例接受基因检测的患儿中15例(47%)携带可能与急性坏死性脑病风险相关的遗传风险等位基因,其中11例(34%)为RANBP2变异。
  • 多数患儿接受多种免疫调节治疗:甲泼尼龙95%、静脉注射免疫球蛋白66%、托珠单抗51%、血浆置换32%。

适用人群与场景

  • 年龄21岁及以下、经实验室确诊流感感染且影像学证实急性丘脑损伤的急性脑病患儿。
  • 病例报告时间段为2023年10月1日至2025年5月30日,来自美国23家医院。
  • 41例中31例(76%)无显著病史,5例(12%)为医学复杂患儿。

诊断标准与关键阈值

  • 纳入标准:急性脑病伴影像学证实的急性丘脑损伤,且实验室确诊流感感染,年龄21岁及以下。

处置流程与药物剂量

  • 多数患儿接受多种免疫调节治疗,包括甲泼尼龙(95%)、静脉注射免疫球蛋白(66%)、托珠单抗(51%)、血浆置换(32%)、阿那白滞素(5%)和鞘内注射甲泼尼龙(5%)。

红旗征与不能漏的情况

  • 脑病见于全部41例(100%),癫痫发作见于28例(68%),发热见于38例(93%)。
  • 死亡病例主要死因为脑疝(占死亡的91%)。

研究设计与关键结果

  • 研究类型为多中心病例系列,共纳入41例来自美国23家医院的患儿(23例女性;中位年龄5岁,IQR 2-8)。
  • 临床表现:发热38例(93%)、脑病41例(100%)、癫痫发作28例(68%);39例(95%)为甲型流感(14例A/H1pdm/2009、7例A/H3N2、18例未分亚型),2例为乙型流感。
  • 实验室异常:肝酶升高78%、血小板减少63%、脑脊液蛋白升高63%。
  • 32例(78%)接受基因检测,其中15例(47%)携带可能与急性坏死性脑病风险相关的遗传风险等位基因,11例(34%)为RANBP2变异。
  • 38例有疫苗接种史记录,仅6例(16%)接种了适龄季节性流感疫苗。
  • 中位重症监护室住院时间和总住院时间分别为11天(IQR 4-19)和22天(IQR 7-36)。
  • 11例(27%)死亡,中位死亡时间为症状出现后3天(IQR 2-4),主要死因为脑疝(91%)。
  • 27例存活者中,63%在90天随访时改良Rankin量表评分≥3(至少中度残疾)。

证据类型、等级与局限

  • 证据类型:多中心病例系列。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,研究结果强调需要预防、早期识别、强化治疗和标准化管理方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Acute necrotizing encephalopathy (ANE) is a rare, but severe, neurologic condition for which epidemiologic and management data remain limited. During the 2024-2025 US influenza season, clinicians at large pediatric centers anecdotally reported an increased number of children with influenza-associated ANE, prompting this national investigation.

OBJECTIVE: To understand the clinical presentation, interventions, and outcomes among US children diagnosed with influenza-associated ANE.

DESIGN, SETTING, AND PARTICIPANTS: This study was a multicenter case series of children diagnosed with ANE with longitudinal follow-up. A call for cases was issued via academic societies, public health agencies, and by directly contacting pediatric specialists at 76 US academic centers, requesting cases between October 1, 2023, and May 30, 2025. Inclusion criteria required acute encephalopathy with radiologic evidence of acute thalamic injury and laboratory confirmation of influenza infection in individuals aged 21 years or younger.

EXPOSURE: Influenza-associated ANE.

MAIN OUTCOMES AND MEASURES: Presenting symptoms, vaccination history, laboratory and genetic findings, interventions, and clinical outcomes, including modified Rankin Scale score (0: no symptoms; 1-2: mild disability; 3-5: moderate to severe disability; 6: death), length of stay, and functional outcomes.

RESULTS: Of 58 submitted cases, 41 cases (23 females; median age, 5 years [IQR, 2-8]) from 23 US hospitals met inclusion criteria. Thirty-one cases (76%) had no significant medical history; 5 (12%) were medically complex. Clinical presentation included fever in 38 patients (93%), encephalopathy in 41 (100%), and seizures in 28 (68%). Thirty-nine patients (95%) had influenza A (14 with A/H1pdm/2009, 7 with A/H3N2, and 18 with no subtype) and 2 had influenza B. Laboratory deviations included elevated liver enzymes (78%), thrombocytopenia (63%), and elevated cerebrospinal fluid protein (63%). Among 32 patients (78%) with genetic testing, 15 (47%) had genetic risk alleles potentially related to risk of ANE including 11 (34%) with RANBP2 variants. Among 38 patients with available vaccination history, only 6 (16%) had received age-appropriate seasonal influenza vaccination. Most patients received multiple immunomodulatory treatments, including methylprednisolone (95%), intravenous immunoglobulin (66%), tocilizumab (51%), plasmapheresis (32%), anakinra (5%), and intrathecal methylprednisolone (5%). Median intensive care unit and hospital lengths of stay were 11 days (IQR, 4-19) and 22 days (IQR, 7-36), respectively. Eleven patients (27%) died a median of 3 days (IQR, 2-4) from symptom onset, primarily from cerebral herniation (91%). Among the 27 survivors with 90-day follow-up, 63% had at least moderate disability (modified Rankin Scale score ≥3).

CONCLUSIONS AND RELEVANCE: In this case series of children with influenza-associated ANE from the 2 most recent influenza seasons in the US, the condition was associated with high morbidity and mortality in this cohort of predominantly young and previously healthy children. The findings emphasize the need for prevention, early recognition, intensive treatment, and standardized management protocols.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Silverman A, Walsh R, Santoro JD, et al. Influenza-Associated Acute Necrotizing Encephalopathy in US Children. JAMA. 2025. PMID: 40736730. doi:10.1001/jama.2025.11534

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。